DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy

Journal of Immunology

Volumn 194, Issue 7, 2015, Pages 3201-3212

  Töpfer, Katrin ^a   Cartellieri, Marc ^b   Michen, Susanne ^a   Wiedemuth, Ralf ^a   Müller, Nadja ^a   Lindemann, Dirk ^c   Bachmann, Michael ^b   Füssel, Monika ^d   Schackert, Gabriele ^a   Temme, Achim ^a,e  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d DKMS Life Science Lab GmbH   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3ZETA CHIMERIC ANTIGEN RECEPTOR; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; IMMUNOMODULATING AGENT; PROSTATE STEM CELL ANTIGEN DAP12 PROTEIN ANTIBODY; PROTEIN KINASE ZAP 70; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; CD3 ANTIGEN; CD3 ANTIGEN, ZETA CHAIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYBRID PROTEIN; MEMBRANE PROTEIN; NATURAL KILLER CELL RECEPTOR; PSCA PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN; TYROBP PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ENGINEERING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSS LINKING; CYTOKINE RELEASE; DRUG CYTOTOXICITY; EMBRYO; ENZYME PHOSPHORYLATION; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; CELL LINE; CYTOTOXICITY; DISEASE MODEL; DRUG SCREENING; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; METABOLISM; MORTALITY; NEOPLASMS; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CELL LINE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; GPI-LINKED PROTEINS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; MICE; NEOPLASM PROTEINS; NEOPLASMS; PHENOTYPE; PHOSPHORYLATION; RECEPTORS, NATURAL KILLER CELL; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84925852082     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400330     Document Type: Article

References (73)

1. Kalos, M., B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, and C. H. June. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3: 95ra73.
2. Davila, M. L., R. Brentjens, X. Wang, I. Rivière, and M. Sadelain. 2012. How do CARs work?: Early insights from recent clinical studies targeting CD19. OncoImmunology 1: 1577-1583.
3. Brentjens, R. J., and K. J. Curran. 2012. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology (Am Soc Hematol Educ Program) 2012: 143-151.
4. Brooks, A. G., J. C. Boyington, and P. D. Sun. 2000. Natural killer cell recognition of HLA class I molecules. Rev. Immunogenet. 2: 433-448.
5. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9: 495-502.
6. Moretta, L., and A. Moretta. 2004. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 23: 255-259.
7. Colonna, M., F. Navarro, T. Bellón, M. Llano, P. García, J. Samaridis, L. Angman, M. Cella, and M. López-Botet. 1997. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 186: 1809-1818.
8. Brooks, A. G., P. E. Posch, C. J. Scorzelli, F. Borrego, and J. E. Coligan. 1997. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J. Exp. Med. 185: 795-800.
9. Petrie, E. J., C. S. Clements, J. Lin, L. C. Sullivan, D. Johnson, T. Huyton, A. Heroux, H. L. Hoare, T. Beddoe, H. H. Reid, et al. 2008. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence. J. Exp. Med. 205: 725-735.
10. Colonna, M., G. Borsellino, M. Falco, G. B. Ferrara, and J. L. Strominger. 1993. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc. Natl. Acad. Sci. USA 90: 12000-12004.
11. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
12. Hansasuta, P., T. Dong, H. Thananchai, M. Weekes, C. Willberg, H. Aldemir, S. Rowland-Jones, and V. M. Braud. 2004. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 34: 1673-1679.
13. Uhrberg, M., N. M. Valiante, B. P. Shum, H. G. Shilling, K. Lienert-Weidenbach, B. Corliss, D. Tyan, L. L. Lanier, and P. Parham. 1997. Human diversity in killer cell inhibitory receptor genes. Immunity 7: 753-763.
14. Ruggeri, L., A. Mancusi, E. Burchielli, K. Perruccio, F. Aversa, M. F. Martelli, and A. Velardi. 2006. Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. Semin. Cancer Biol. 16: 404-411.
15. Gumperz, J. E., V. Litwin, J. H. Phillips, L. L. Lanier, and P. Parham. 1995. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181: 1133-1144.
16. Kärre, K. 1995. Express yourself or die: peptides, MHC molecules, and NK cells. Science 267: 978-979.
17. Colonna, M., E. G. Brooks, M. Falco, G. B. Ferrara, and J. L. Strominger. 1993. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 260: 1121-1124.
18. Rose, M. J., A. G. Brooks, L. A. Stewart, T. H. Nguyen, and A. P. Schwarer. 2009. Killer Ig-like receptor ligand mismatch directs NK cell expansion in vitro. J. Immunol. 183: 4502-4508.
19. Smyth, M. J., E. Cretney, J. M. Kelly, J. A. Westwood, S. E. Street, H. Yagita, K. Takeda, S. L. van Dommelen, M. A. Degli-Esposti, and Y. Hayakawa. 2005. Activation of NK cell cytotoxicity. Mol. Immunol. 42: 501-510.
20. Oshimi, Y., S. Oda, Y. Honda, S. Nagata, and S. Miyazaki. 1996. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J. Immunol. 157: 2909-2915.
21. Müller, T., C. Uherek, G. Maki, K. U. Chow, A. Schimpf, H. G. Klingemann, T. Tonn, and W. S. Wels. 2008. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol. Immunother. 57: 411-423.
22. Chu, J., Y. Deng, D. M. Benson, S. He, T. Hughes, J. Zhang, Y. Peng, H. Mao, L. Yi, K. Ghoshal, et al. 2014. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28: 917-927.
23. Uherek, C., T. Tonn, B. Uherek, S. Becker, B. Schnierle, H. G. Klingemann, and W. Wels. 2002. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100: 1265-1273.
24. Ford, J. W., and D. W. McVicar. 2009. TREM and TREM-like receptors in inflammation and disease. Curr. Opin. Immunol. 21: 38-46.
25. Bakker, A. B., E. Baker, G. R. Sutherland, J. H. Phillips, and L. L. Lanier. 1999. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc. Natl. Acad. Sci. USA 96: 9792-9796.
26. Lanier, L. L., B. Corliss, J. Wu, and J. H. Phillips. 1998. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 8: 693-701.
27. Campbell, K. S., S. Yusa, A. Kikuchi-Maki, and T. L. Catina. 2004. NKp44 triggers NK cell activation through DAP12 association that is not influenced by a putative cytoplasmic inhibitory sequence. J. Immunol. 172: 899-906.
28. Carr, W. H., D. B. Rosen, H. Arase, D. F. Nixon, J. Michaelsson, and L. L. Lanier. 2007. Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J. Immunol. 178: 647-651.
29. Della Chiesa, M., E. Romeo, M. Falco, M. Balsamo, R. Augugliaro, L. Moretta, C. Bottino, A. Moretta, and M. Vitale. 2008. Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function. Eur. J. Immunol. 38: 2284-2289.
30. Hayley, M., S. Bourbigot, and V. Booth. 2011. Self-association of an activating natural killer cell receptor, KIR2DS1. PLoS ONE 6: e23052.
31. Lanier, L. L., B. C. Corliss, J. Wu, C. Leong, and J. H. Phillips. 1998. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391: 703-707.
32. Gumá, M., A. Angulo, C. Vilches, N. Gómez-Lozano, N. Malats, and M. López-Botet. 2004. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104: 3664-3671.
33. Gumá, M., M. Budt, A. Sáez, T. Brckalo, H. Hengel, A. Angulo, and M. López-Botet. 2006. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107: 3624-3631.
34. Kuijpers, T. W., P. A. Baars, C. Dantin, M. van den Burg, R. A. van Lier, and E. Roosnek. 2008. Human NK cells can control CMV infection in the absence of T cells. Blood 112: 914-915.
35. Morgenroth, A., M. Cartellieri, M. Schmitz, S. Günes, B. Weigle, M. Bachmann, H. Abken, E. P. Rieber, and A. Temme. 2007. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 67: 1121-1131.
36. Dannull, J., P. A. Diener, L. Prikler, G. Fürstenberger, T. Cerny, U. Schmid, D. K. Ackermann, and M. Groettrup. 2000. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 60: 5522-5528.
37. Ross, S., S. D. Spencer, I. Holcomb, C. Tan, J. Hongo, B. Devaux, L. Rangell, G. A. Keller, P. Schow, R. M. Steeves, et al. 2002. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 62: 2546-2553.
38. Saffran, D. C., A. B. Raitano, R. S. Hubert, O. N. Witte, R. E. Reiter, and A. Jakobovits. 2001. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Natl. Acad. Sci. USA 98: 2658-2663.
39. Reiter, R. E., Z. Gu, T. Watabe, G. Thomas, K. Szigeti, E. Davis, M. Wahl, S. Nisitani, J. Yamashiro, M. M. Le Beau, et al. 1998. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 95: 1735-1740.
40. Lam, J. S., J. Yamashiro, I. P. Shintaku, R. L. Vessella, R. B. Jenkins, S. Horvath, J. W. Said, and R. E. Reiter. 2005. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin. Cancer Res. 11: 2591-2596.
41. Elsamman, E. M., T. Fukumori, S. Tanimoto, R. Nakanishi, M. Takahashi, K. Toida, and H. O. Kanayama. 2006. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. BJU Int. 98: 668-673.
42. Argani, P., C. Rosty, R. E. Reiter, R. E. Wilentz, S. R. Murugesan, S. D. Leach, B. Ryu, H. G. Skinner, M. Goggins, E. M. Jaffee, C. J. Yeo, J. L. Cameron, S. E. Kern, and R. H. Hruban. 2001. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 61: 4320-4324.
43. Geiger, K. D., S. Hendruschk, E. P. Rieber, A. Morgenroth, B. Weigle, T. Juratli, V. Senner, G. Schackert, and A. Temme. 2011. The prostate stem cell antigen represents a novel glioma-associated antigen. Oncol. Rep. 26: 13-21.
44. Thomas-Kaskel, A. K., R. Zeiser, R. Jochim, C. Robbel, W. Schultze-Seemann, C. F. Waller, and H. Veelken. 2006. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int. J. Cancer 119: 2428-2434.
45. Waeckerle-Men, Y., E. Uetz-von Allmen, M. Fopp, R. von Moos, C. Böhme, H. P. Schmid, D. Ackermann, T. Cerny, B. Ludewig, M. Groettrup, and S. Gillessen. 2006. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol. Immunother. 55: 1524-1533.
46. Kiessling, A., M. Schmitz, S. Stevanovic, B. Weigle, K. Hölig, M. Füssel, S. Füssel, A. Meye, M. P. Wirth, and E. P. Rieber. 2002. Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int. J. Cancer 102: 390-397.
47. Cohen, G. B., R. T. Gandhi, D. M. Davis, O. Mandelboim, B. K. Chen, J. L. Strominger, and D. Baltimore. 1999. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10: 661-671.
48. Amer, D. A., G. Kretzschmar, N. Müller, N. Stanke, D. Lindemann, and G. Vollmer. 2010. Activation of transgenic estrogen receptor-beta by selected phytoestrogens in a stably transduced rat serotonergic cell line. J. Steroid Biochem. Mol. Biol. 120: 208-217.
49. Zufferey, R., J. E. Donello, D. Trono, and T. J. Hope. 1999. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73: 2886-2892.
50. Mochizuki, H., J. P. Schwartz, K. Tanaka, R. O. Brady, and J. Reiser. 1998. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol. 72: 8873-8883.
51. Kalajzic, I., M. L. Stover, P. Liu, Z. Kalajzic, D. W. Rowe, and A. C. Lichtler. 2001. Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells. Virology 284: 37-45.
52. Sutlu, T., S. Nyström, M. Gilljam, B. Stellan, S. E. Applequist, and E. Alici. 2012. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Hum. Gene Ther. 23: 1090-1100.
53. Burshtyn, D. N., J. Shin, C. Stebbins, and E. O. Long. 2000. Adhesion to target cells is disrupted by the killer cell inhibitory receptor. Curr. Biol. 10: 777-780.
54. Maghazachi, A. A. 2005. Insights into seven and single transmembrane-spanning domain receptors and their signaling pathways in human natural killer cells. Pharmacol. Rev. 57: 339-357.
55. Restifo, N. P., M. E. Dudley, and S. A. Rosenberg. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-281.
56. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
57. Rosenberg, S. A. 2008. Overcoming obstacles to the effective immunotherapy of human cancer. Proc. Natl. Acad. Sci. USA 105: 12643-12644.
58. Hombach, A., J. M. Muche, M. Gerken, S. Gellrich, C. Heuser, C. Pohl, W. Sterry, and H. Abken. 2001. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells. Gene Ther. 8: 891-895.
59. Hombach, A., C. Schlimper, E. Sievers, S. Frank, H. H. Schild, T. Sauerbruch, I. G. Schmidt-Wolf, and H. Abken. 2006. A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells. Gut 55: 1156-1164.
60. Lindencrona, J. A., S. Preiss, T. Kammertoens, T. Schüler, M. Piechocki, W. Z. Wei, B. Seliger, T. Blankenstein, and R. Kiessling. 2004. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int. J. Cancer 109: 259-264.
61. Hillerdal, V., B. Nilsson, B. Carlsson, F. Eriksson, and M. Essand. 2012. T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells. Proc. Natl. Acad. Sci. USA 109: 15877-15881.
62. Morgan, R. A., L. A. Johnson, J. L. Davis, Z. Zheng, K. D. Woolard, E. A. Reap, S. A. Feldman, N. Chinnasamy, C. T. Kuan, H. Song, et al. 2012. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23: 1043-1053.
63. Kong, S., S. Sengupta, B. Tyler, A. J. Bais, Q. Ma, S. Doucette, J. Zhou, A. Sahin, B. S. Carter, H. Brem, et al. 2012. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptormodified T cells. Clin. Cancer Res. 18: 5949-5960.
64. Sampson, J. H., B. D. Choi, L. Sanchez-Perez, C. M. Suryadevara, D. J. Snyder, C. T. Flores, S. K. Nair, R. J. Schmittling, E. A. Reap, P. K. Norberg, et al. 2014. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin. Cancer Res. 20: 972-984.
65. Esser, R., T. Müller, D. Stefes, S. Kloess, D. Seidel, S. D. Gillies, C. Aperlo-Iffland, J. S. Huston, C. Uherek, K. Schönfeld, et al. 2012. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J. Cell. Mol. Med. 16: 569-581.
66. Kruschinski, A., A. Moosmann, I. Poschke, H. Norell, M. Chmielewski, B. Seliger, R. Kiessling, T. Blankenstein, H. Abken, and J. Charo. 2008. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl. Acad. Sci. USA 105: 17481-17486.
67. Schonfeld, K., C. Sahm, C. Zhang, S. Naundorf, C. Brendel, M. Odendahl, P. Nowakowska, H. Bonig, U. Kohl, S. Kloess, et al. 2015. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol. Ther. 23: 330-338.
68. Schirrmann, T., and G. Pecher. 2002. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther. 9: 390-398.
69. Hamerman, J. A., N. K. Tchao, C. A. Lowell, and L. L. Lanier. 2005. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat. Immunol. 6: 579-586.
70. Turnbull, I. R., and M. Colonna. 2007. Activating and inhibitory functions of DAP12. Nat. Rev. Immunol. 7: 155-161.
71. Sadelain, M., R. Brentjens, and I. Rivière. 2009. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21: 215-223.
72. Craddock, J. A., A. Lu, A. Bear, M. Pule, M. K. Brenner, C. M. Rooney, and A. E. Foster. 2010. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33: 780-788.
73. Moon, E. K., C. Carpenito, J. Sun, L. C. Wang, V. Kapoor, J. Predina, D. J. Powell, Jr., J. L. Riley, C. H. June, and S. M. Albelda. 2011. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17: 4719-4730.